MA-ABIOMED
Abiomed (Nasdaq: ABMD) will highlight how Impella heart pumps help heart teams achieve more complete high-risk revascularization and heart recovery in the catheterization lab and operating room at the Transcatheter Cardiovascular Therapeutics (TCT) 2022 Conference, held in Boston from September 16 to 19.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220913005521/en/
Impella 5.5 with SmartAssist delivers full cardiac support with maximum unloading, allowing the heart to rest and recover. (Graphic: Business Wire)
During the conference, physician-researchers will present clinical data demonstrating Impella leads to higher survival rates for cardiogenic shock patients and quality of life improvements for heart failure patients. Additional presentations and live cases will describe how Impella innovation and best practices have advanced safety and ease-of-use. Attendees can also receive hands-on Impella training and learn about future Impella technology.
Clinical Data Presentations:
Impella will be featured in presentations on topics that include a new analysis of data from the STEMI-DTU pilot randomized controlled trial and new data on cardiogenic shock and myocarditis outcomes from the J-PVAD registry in Japan. The J-PVAD registry is overseen by 10 Japanese professional societies, including the Japanese Circulation Society.
Abiomed’s preCARDIA technology to treat acute decompensated heart failure (ADHF) will be featured in two presentations that provide data showing preCARDIA reduces stressed blood volume and improves urine sodium excretion in ADHF patients.
Additionally, Abiomed will host two symposia with physician-researchers discussing the benefits of Impella as a therapy for patients in cardiogenic shock and Impella-supported high-risk PCI. They are:
- From Shock Spiral to Survival: Achieving Heart Recovery in Cardiogenic Shock – This in-person symposium takes place on Saturday, September 17, from 12:45–1:45 pm EDT in the TCT Presentation Theatre. Navin K. Kapur, MD, Tufts Medical Center, Boston; Katherine Kunkel, MD, Piedmont Heart Institute, Atlanta; Junya Ako, MD, Kitasato University Hospital, Tokyo; and Jay Giri, MD, MPH, Penn Medicine, Philadelphia, will present on best practices for Impella use to improve cardiogenic shock survival. A panel discussion will take place that will also include William O’Neill, MD and Mir Babar Basir, DO, from Henry Ford Hospital, Detroit.
- The CAD’s Out of the Bag: Achieving Heart Recovery in High-Risk Revascularization – This symposium is in-person and will be live streamed from the TCT World Connect Theatre on Sunday, September 18, from 12:30–1:30 pm EDT. Jonathan Hill, MD, Royal Brompton and Harefield Hospital, London; and Kate Kearney, MD, University of Washington, Seattle, will discuss clinical trials and best practices for Impella-supported high-risk PCI. Additionally, Navin K. Kapur, MD, Tufts Medical Center, Boston, will discuss ventricular unloading and what can be learned from the STEMI-DTU randomized controlled trial. A panel discussion will take place that will also include Gregg Stone, MD, Mount Sinai Health System, New York; Amir Kaki, MD, Ascension St. John Hospital, Detroit; and Cindy Grines, MD, Northside Hospital, Atlanta.
A detailed agenda for each symposium is available at this link on the TCT website.
Technology and Training:
Physicians attending the conference can receive hands-on Impella best practice training in the TCT Training Pavilion on topics such as access and closure, Impella RP with SmartAssist insertion and advanced Impella management. The esteemed faculty teaching these courses are Rajiv Tayal, MD, Valley Health System, Ridgewood, NJ; Robert Salazar, MD, Memorial Hermann, Houston; and Dan Burkhoff, MD, PhD, Cardiovascular Research Foundation. A detailed agenda for each training is available at this link on the TCT website.
Conference attendees are invited to visit the Abiomed booth, in the TCT Exhibit Hall. Abiomed’s booth will feature the latest Impella technology, including Impella 5.5 with SmartAssist and Impella RP with SmartAssist. Future pipeline technology will be available to preview, including Impella ECP, Impella RP Flex, Impella BTR and preCARDIA. Additionally, advanced Impella trainers will be available to answer questions about Impella’s new heparin-free purge, provide a hands-on experience with the Impella simulator and guide attendees through Abiomed’s new virtual reality training technology.
Live Daily Recap Program:
Abiomed’s TCT daily recap program will broadcast live from 6:00–6:30 pm EDT on Saturday, September 17 through Monday, September 19. The program will summarize the day’s news from TCT. It will be hosted by Abiomed’s chief medical officer, Chuck Simonton, MD, and Abiomed’s vice president for professional education and medical communication, Seth Bilazarian, MD. To watch live, log on to www.heartrecovery.com.
ABOUT IMPELLA HEART PUMPS
The Impella 2.5® and Impella CP® with SmartAssist® are U.S. FDA approved to treat certain advanced heart failure patients undergoing elective and urgent percutaneous coronary interventions (PCI), such as stenting or balloon angioplasty, to reopen blocked coronary arteries.
Impella 2.5, Impella CP®, Impella CP with SmartAssist, Impella 5.0®, Impella LD® and Impella 5.5® with SmartAssist® are U.S. FDA approved to treat heart attack or cardiomyopathy patients in cardiogenic shock and have the unique ability to enable native heart recovery, allowing patients to return home with their own heart.
Impella RP® and Impella RP® with SmartAssist are U.S. FDA approved to treat right heart failure or decompensation following left ventricular assist device implantation, myocardial infarction, heart transplant or open-heart surgery.
ABOUT ABIOMED
Based in Danvers, Massachusetts, USA, Abiomed, Inc., is a leading provider of medical technology that provides circulatory support and oxygenation. Our products are designed to enable the heart to rest by improving blood flow and/or provide sufficient oxygenation to those in respiratory failure. For additional information, please visit: http://www.abiomed.com.
FORWARD-LOOKING STATEMENTS
Any forward-looking statements are subject to risks and uncertainties such as those described in Abiomed's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220913005521/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom